Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 6/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3374875 | 0.77 | CYP1A2 (0.46) | TSHRSLC18A3SIGMAR1TACR1CYP1A2 | |
| SCHEMBL3374873 | 0.77 | CYP1A2 (0.46) | TSHRSLC18A3SIGMAR1TACR1CYP1A2 | |
| SCHEMBL22570100 | 0.77 | TACR1 (0.46) | TSHRSLC18A3SIGMAR1TACR1CYP1A2 | |
| SCHEMBL7919080 | 0.77 | GBA1 (0.52) | TSHRSLC18A3SIGMAR1TACR1CYP1A2 | |
| SCHEMBL4029350 | 0.77 | CYP1A2 (0.46) | TSHRSLC18A3SIGMAR1TACR1CYP1A2 | |
| SCHEMBL25360423 | 0.77 | TACR1 (0.46) | TSHRSLC18A3SIGMAR1TACR1CYP1A2 | |
| SCHEMBL21163277 | 0.77 | TACR1 (0.46) | TSHRSLC18A3SIGMAR1TACR1CYP1A2 | |
| SCHEMBL22570096 | 0.77 | TACR1 (0.46) | TSHRSLC18A3SIGMAR1TACR1CYP1A2 | |
| SCHEMBL13069094 | 0.77 | CYP1A2 (0.46) | TSHRSLC18A3SIGMAR1TACR1CYP1A2 | |
| SCHEMBL6248843 | 0.77 | GBA1 (0.52) | TSHRSLC18A3SIGMAR1TACR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119207-B2 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1272484-B1 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PROD INC (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1515708-A1 | COMBINATIONS OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | Pfizer Products Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | disclosed |
| US-20040001895-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-01 | — | — | US | disclosed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003105815-A1 | COMBINATION OF PDE-V INHIBITORS AND NK1 ANTAGONISTS FOR THE TREATMENT OF DEPRESSION | PFIZER PRODUCTS INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1272484-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | disclosed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001077100-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | TSHR 539/4885SLC18A3 72/4885SIGMAR1 374/4885 |
| US-20040001895-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, ADORA1 | TSHR 864/4885SLC18A3 125/4885SIGMAR1 434/4885 |
| US-20020049211-A1 | Combination treatment for depression and anxiety | HTR1A, HTR1D, HTR5A | TSHR 477/4885SLC18A3 132/4885SIGMAR1 221/4885 |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | TACR1, VIPR1, VIPR2 | TSHR 2536/4885SLC18A3 1996/4885SIGMAR1 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.